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SUPPLEMENTARY NOTES
ABSTRACT
About one out of every ten cases of epithelial ovarian cancer (EOC) is inherited. The majority, >90%, of inherited cases of EOC are the result of mutations in the breast cancer associated gene 1 {BRCAl). This gene was originally identified based on genetic linkage to families with an increased risk of developing breast and ovarian cancer. It is involved in controlling normal cellular growth and is thought to suppress the growth of tumors. That is, if BRCAl is mutated, the risk to develop breast and ovarian, cancer increases. Another gene that is important in the development of cancer is p53. It also helps maintain normal cellular growth and is the most commonly mutated gene in all human cancers. The p53 gene has been shown to be mutated in at least 50% of all cases of epithelial ovarian cancer. In addition to mutations of BRCAl, mutations of the p53 gene are often found in patients with breast and ovarian cancer syndrome. Based on the importance of both of these genes in the development of this type of ovarian cancer, we hypothesize that inactivation of BRCAl and p53 in the ovaries of mice will result in epithelial ovarian cancer in the animals.
SUBJECT TERMS
Ovarian Cancer, p53, BRCA1 About one out of every ten cases of epithelial ovarian cancer is inherited. Unlike non-hereditary (sporadic) ovarian cancer, some of the underlying genetic causes of hereditary ovarian cancer are well understood. The majority, >90%, of inherited cases are the result of inherited mutations in the breast cancer associated gene 1 (BRCA1). This gene was originally identified based on genetic linkage to families with an increased risk of developing breast and ovarian cancer. It is involved in controlling normal cellular growth and is thought to suppress the growth of tumors. That is, if BRCA1 is mutated, the risk to develop breast and ovarian cancer increases. Another gene that is important in the development of cancer is the p53 gene. It also helps maintain normal cellular growth and is the most commonly mutated gene in all human cancers. It has been shown to be mutated in at least 50% of all cases of epithelial ovarian cancer. In addition to mutations of BRCA1, mutations of the p53 gene are often found in patients with breast and ovarian cancer syndrome. Based on the importance of both of these genes in the development of this type of ovarian cancer, we hypothesize that inactivation of BRCA1 and p53 in the ovaries of mice will result in epithelial ovarian cancer in the animals.
MODELING HUMAN EPITHELIAL OVARIAN CANCER IN MICE BY ALTERATION OF EXPRESSION OF THE
The objectives of this funded proposal are to:
1. develop mouse models of human epithelial ovarian cancer by inactivation of Brca1 and p53 singly or at the same time in the mouse ovarian surface epithelial cells; 2. investigate whether there is a difference between the complete absence of p53 or the presence of a dominantly acting p53 mutant in ovarian tumorigenesis in mice; and, 3. identify genes and cellular pathways, downstream of Brca1 and p53 inactivation/mutation, that contribute to ovarian carcinogenesis.
Body:
Specific tasks that were completed during the one year extension were 1) euthanasia and necropsy of remaining mice, 2) histopathological evaluation of tumor tissues, 2) verification of excision of conditional alleles in tumor tissue and 4) evaluation of genomic changes in a subset of tumors. All procedures described in this progress report involving animals were approved by Fox Chase Institutional Animal Care and Use Committee.
At the time of the 2007 progress report, a total of 161 mice had been euthanized and evaluated with 55 mice remaining alive on the study. Since then, the remaining 55 mice were euthanized and evaluated. Animals were euthanized if they exhibited palpable tumors or signs of illness or because they had reached old age without any symptoms of disease. In the absence of symptoms of disease, most animals were euthanized by the time they reached ~500 days in age. In rare cases animals that had expired overnight or over weekends were considered not suitable for tissue collection and further evaluation which accounts for small differences in the total numbers of mice injected versus the total number of mice evaluated. A summary of the total number of animals that were evaluated in each group is presented in Table 1 . All animals were euthanized by CO 2 asphyxiation and were subjected to complete necropsy with gross pathological evaluation. All reproductive tract tissues and other affected tissues were removed and either fixed and processed for paraffin embedding and tissue sectioning or snap frozen in liquid nitrogen. Paraffin embedded tissue sections of reproductive tracts and all affected tissues were stained with hematoxylin and eosin (H&E) and evaluated microscopically by the PI (D. Connolly) and by Dr. Lora Hedrick Ellenson, a board certified Gynecological Pathologist at Weill Cornell Medical College in New York. Paraffin embedded tissues of a number of tumors and affected tissues were also subject to immunohistochemical staining with antibodies to detect various cellular markers of differentiation (e.g., cytokeratin 8, cytokeratin 19, CD3, CD45 and α-smooth muscle actin) to assist in diagnosis of tumor histopathology. To confirm that tumor formation observed in mice is attributable to loss of Brca1 and/or p53 expression, tumor specimens were analyzed for excision of loxP flanked (floxed) sequences by PCR of genomic DNA isolated from tumor specimens. Genomic DNA from tumor specimens was isolated from snap frozen tumor specimens for large tumor specimens or by manual microdissection of neoplastic lesions identified in paraffin embedded and sectioned tissues. Over the course of the entire study, a total of 216 mice were euthanized and evaluated for tumor formation ( Table 1) . At the time of submission of this final progress report, all of the mice in Groups I-V have been evaluated. Of the 216 total mice evaluated, a number of neoplasms were observed and are summarized in Table 2 (Ad5-CMV-Cre injected mice) and Table 3 (PBS injected mice). Mice in Group I (Brca1
LoxP/LoxP
) in which the Brca1 gene was inactivated by Ad5-CMV-Cre injection developed neoplasms with a frequency of ~20% (9/42 mice). Only one ovarian neoplasm was identified and that was hilar cell tumor of the ovary. In one case (1/46 = 2.1%), we observed a vaginal squamous adenocarcinoma and two animals (2/46 = 4.3 %) had large masses over the front flank/shoulder that were identified as adenocarcinomas. Adenocarcinoma of the lung was observed in 4/46 (8.7 %) of the Ad5-Cre-CMV injected mice and in 1/6 (16.7 %) of the PBS control injected mice. The vaginal, shoulder and lung tumors in these mice were manually microdissected and subjected to genotyping analysis to confirm whether the floxed sequences present in the Brca1 gene of these mice was excised. In none of these 7 cases were we able to demonstrate excision of the floxed sequences present in the Brca1 gene were excised suggesting that these tumors are not related to loss of expression of Brca1. Tumors were observed in only three of 45 (6.6%) cases in Group II (p53
) in which the p53 gene was inactivated. Of these, two ovarian neoplasms were identified; one ovarian leiomyosarcoma (excision of both Brca1 and p53 alleles was confirmed by PCR amplification) and one ovarian hilar cell tumor. As predicted, the highest frequency of tumors observed to date were in the Ad5-CMV-Cre injected mice in Group III (Brca1 LoxP/LoxP ;p53 LoxP/LoxP ) in which both the Brca1 and/or p53 genes were inactivated. Tumors were observed in 52% (22/42) mice in this group. Ovarian tumors were observed in 26% (11/42) of these mice. Surprisingly, we did not observe epithelial ovarian tumors; rather, the ovarian tumors were poorly differentiated leiomyosarcoma of the ovary (Figure 1) . Other tumors observed in this group were primarily (21%, 9/24 cases) poorly differentiated non-ovarian peritoneal sarcomas without distinct morphologic or immunohistochemical features. In Group IV (Brca1 LoxP/LoxP ;p53 WT/R172H ), in mice harboring homozygous floxed Brca1, one wild-type and one copy of a gain of function hot spot mutation p53, neoplasms were observed in 28% (10/36) mice, but none were ovarian tumors nor could excision of the Brca1 allele be demonstrated in any of these tumor tissues by PCR. Mice harboring a single copy of this mutant p53 allele are known to develop spontaneous tumors with similar latency and histology as tumors that arise in p53 +/-(1). We predicted that concomitant loss of expression of Brca1 in the mouse ovary might result in epithelial ovarian cancers that outpaced these spontaneous tumors, but that does not seem to be the case in these mice. Based on these results we modified our experimental plan for Group V (Brca1
LoxP/R172H ), and reduced the number of mice in this arm as it is expected that these mice would also be susceptible to spontaneous tumor formation related to the presence of the p53 R172H allele. Accordingly, we reduced the number of mice in this arm by approximately half ( LoxP/R172H mice that received intrabursal injection of Ad5-CMV-Cre, 3/18 (16.6%) developed tumors. In one case of peritoneal sarcoma adjacent to the ovary was shown to have excision of the Brca1 allele, whereas the one case of lymphoma there was no excision of the floxed sequences in Brca1. Table 2 . Summary of observed pathology in mice injected with Ad5-CMV-Cre. Number indicated is the percent and the numbers in parentheses are the number of mice with the indicated neoplasm out of the total number of mice in the group. All tumors were analyzed by microscopic evaluation of H&E stained tissue sections as well as tissue sections stained with various specific markers of cellular differentiation (e.g., cytokeratin 8, cytokeratin 19, CD3, CD45 and α-smooth muscle actin). Results from immunohistochemical analyses revealed no distinct or predictive staining patterns as many of the sarcomas were negative for these markers. Cases of tumors in which there was sufficient tissue were evaluated by PCR genotyping to confirm the presence or absence of floxed sequences of the Brca1 and/or p53 alleles. In Group III, the group with the highest incidence of tumor formation, most tumors were confirmed to have excision of both Brca1 and p53 alleles. However, in all other groups, excision was relatively infrequent suggesting that tumor formation was sporadic (e.g., in Group I, BrcaA1 
;p53
LoxP/LoxP mice which had the highest incidence, tumor formation occurred with relatively long latency (Table 4) suggesting that other genetic alterations contribute to tumorigenesis in this model. To test this hypothesis, we evaluated gross genomic alterations present in ovarian leiomyosarcomas by array comparative genomic hybridization (aCGH) and karyotyping of a leiomyosarcoma cell line derived from a tumor bearing mouse. These analyses revealed that ovarian sarcomas arising in Brca1
LoxP/LoxP mice were accompanied by dramatic global genomic alterations as shown by both aCGH and karyotyping of the leiomyosarcoma cell line in Figure 2 . The single ovarian sarcoma arising in the p53 LoxP/LoxP group, while not normal, generally had patterns of whole chromosome gains and losses consistent with aneuploidy and many fewer regions of interstitial chromosomal gains/losses detected by aCGH as compared to tumors isolated from Brca1
LoxP/LoxP ;p53
LoxP/LoxP mice (Figure 2 A and C) . These results confirm previous studies showing that global genetic alterations are a common feature in BRCA1 mutation carriers (4, 5) . Table 4 . Average age in days at euthanasia (standard deviation). 
Group
Conclusions:
Inactivation of conditionally expressed loxP flanked alleles of the Brca1 and/or p53 genes in the mouse ovary by intrabursal injection of Adenovirus-Cre recombinase results in a high frequency of ovarian and non-ovarian neoplasms. Unlike a previously reported mouse model of epithelial ovarian cancer resulting from conditional inactivation of the p53 and Rb genes in the mouse ovary (6), the incidence of epithelial ovarian carcinomas is rare in mice with conditional inactivation of both the Brca1 and p53 genes. We have communicated our results with our colleagues at meetings and have learned that other groups performing similar experiments have had similar results. Although this is not the predicted outcome, the results of this study are reportable. A manuscript (Quinn, et al, in preparation) reporting these results is in the final stages of preparation and will be submitted for publication within the next 4-6 weeks.
